Hutchison China MediTech: An emerging global biopharma

5 July 2019

Hutchison China MediTech (AIM: HCM), also known as Chi-Med, has recently announced positive data that key late-stage asset surufatinib met the primary endpoint of PFS in non-pancreatic tumors (NET) sat the Phase III interim analysis.

This translates to an earlier than expected China NDA submission (second half 2019) and the potential launch of HCM’s first un-partnered asset (early 2021), note analysts at Edison Investment Research.

In China, partner Eli Lilly (NYSE: LLY) has launched Elunate (fruquintinib) capsules. Early sales look promising and its potential inclusion on the China national reimbursement drug list (NRDL) later this year will be definitive to the China opportunity.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK